Ursula Theuretzbacher

Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis

Evelina Tacconelli, Elena Carrara, Alessia Savoldi et al. · The Lancet Infectious Diseases · 2017 · 6.1K citations · Full text

Life Sciences, Infectious Diseases, Microbiology +14

Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial

Mical Paul, George L. Daikos, Emanuele Durante‐Mangoni et al. · The Lancet Infectious Diseases · 2018 · 624 citations

Life Sciences, Infectious Diseases, Microbiology +14

Pharmacokinetic/Pharmacodynamic Profile of Voriconazole

Ursula Theuretzbacher, Franziska Ihle, Hartmut Derendorf · Clinical Pharmacokinetics · 2006 · 475 citations

Medicine, Pharmacokinetics, Pharmacology +12

Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus

Roger L. Nation, Jian Li, Otto Cars et al. · The Lancet Infectious Diseases · 2014 · 343 citations

Pharmacy, Clinical Pharmacokinetics, Pharmacotherapy +15

Effect of 5-Day Nitrofurantoin vs Single-Dose Fosfomycin on Clinical Resolution of Uncomplicated Lower Urinary Tract Infection in Women

Angela Huttner, Anna Kowalczyk, ‪Adi Turjeman‬‏ et al. · JAMA · 2018 · 213 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +13